Main Article Content

Bansal Yogesh


Inflammatory markers, COVID-19, SARS-CoV-2, rt PCR


Background: - Coronavirus disease 2019 (COVID-19) was caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in early December 2019. The illness starts out as a respiratory condition with a range of outcomes, including full recovery and long-term sequelae like respiratory difficulties, heart problems, stroke, and death. The goal of the current investigation was to evaluate the levels of advanced markers like inflammatory and non-inflammatory markers to check the severity and, consequently, gauge the prognosis of patients with COVID-19 infection.

Materials and methods: - 144 patients with COVID-19 were included in the study group A and B, and was validated by nasopharyngeal swab RT-PCR for SARS-CoV-2. Information was gathered from medical records. Correlation analysis were carried out and variables compared.

Results- As per statistical analysis, C-reactive protein (P = 0.001), ferritin (P = 0.0001), D-dimer (P = 0.001), lactate dehydrogenase (P = 0.001), aspartate aminotransferase (P= 0.004), and total bilirubin (P = 0.006) levels were found significantly increased in both the groups. Leukocytosis, neutropenia, lymphopenia, and an elevated neutrophil-to-lymphocyte ratio (P = 0.001) were also seen in both the groups.

Conclusion: - Indicators of organ involvement in COVID 19 infection can be assessed via growing levels of inflammatory markers demonstrate that the illness has moved from group A to group B. Leukocytosis, neutrophilia, lymphopenia, and a raised NLR were among the inflammatory markers that were altered in the current study. CRP, ferritin, LDH, and D-dimer levels were also elevated. Increased levels of transaminases and total bilirubin suggest organ (liver) involvement.

Abstract 59 | pdf Downloads 41


1. Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848.
2. Stebbing J., Phelan A., Griffin I., Tucker C., Oechsle O., Smith D. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402
3. Government of India Ministry of Health and Family Welfare: Clinical Management Protocol for COVID-19 (adults).
4. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, Diao K, Lin B, Zhu X, Li K, et al: Chest CT findings in coro¬navirus disease-19 (COVID-19): Relationship to duration of infection. Radiology 295: 200463, 2020.
5. Falasca K, Ucciferri C, Brandimarte A, Auricchio A, Pontolillo M, Caiazzo L and Vecchiet J: Clinical characteris¬tics and cardiovascular implications of the dead patients for COVID-19. Eur J Inflam 19, 2021.
6. Tay M.Z., Poh C.M., Renia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020:1–12.
7. Buyukaydin B: The relationship of hemogram and inflammatory biomarkers to lenght of stay in hospital and clinical course in patients with COVID-19. Bezm Sci 8: 7-14, 2020.
8. Moutchia J, Pokharel P, Kerri A, McGaw K, Uchai S, Nji M and Goodman M: Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. PLoS One 15: e0239802, 2020.
9. Zhao Y, Nie HX, Hu K, Wu XJ, Zhang YT, Wang MM, Wang T, Zheng SC, Li XC and Zeng SL: Abnormal immunity of non¬survivors with COVID-19: predictors for mortality. Infect Dis Poverty 9: 108, 2020.
10. Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020.
11. Kordzadeh-Kermani E, Khalili H and Karimzadeh I: Pathogenesis, clinical manifestations and complications of COVID-19. Future Microbiol 15: 1287-1305, 2020.
12. Thompson S, Bohn MK, Mancini N, Loh TP, Wang CB, Grimmler M, Yuen KY, Mueller R, Koch D, Sethi S, et al: Horvath and the IFCC taskforce on COVID-19. IFCC interim guidelines on biochemical/hematological monitoring of COVID-19 patients. Clin Chem Lab Med 58: 2009-2016, 2020.
13. Danwang C, Endomba FT, Nkeck JR, Wouna DLA, Robert A and Noubiap JJ: A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res 8: 37, 2020.
14. Wu S., Zhou Y., Hua H.Y., Zhang Y., Zhu W.Y., Wang Z.Q. Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma. BMC Cancer. 2018;18(1):997
15. Zenga F, Huangc Y, Guoa Y, Yina M, Chena X, Xiaod L and Deng G: Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis 96: 467-474, 2020.
16. Jurado A, Martin MC, Abad-Molina C, Orduna A, Martinez A, Ocana E, Yarce O, Navas AM, Trujillo A, Fernandez L, et al: COVID-19: Age, interleukin-6, C-reactive protein, and lympho-cytes as key clues from a multicentre retrospective study. Immun Ageing 17: 22, 2020.
17. Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
18. Marfia G, Navone S, Guarnaccia L, Campanella R, Mondoni M, Locatelli M, Barassi A, Fontana L, Palumbo F, Garzia E, et al: Decreased serum level of sphingosine-1-phosphate: A novel predictor of clinical severity in COVID-19. EMBO Mol Med 13: e13424, 2021.
19. Chang Z., Yang W., Wang Q., Liao G. Clinical significance of serum hs-CRP, IL-16, and PCT in diagnosis and prognosis of patients with COVID-19 (In Chinese) Drugs Clin. 2020;35(3).
20. Mirmohammadi S, Kianmehr A, Arefi M and Mahrooz A: Biochemical parameters and pathogenesis of SARS-CoV-2 infec¬tion in vital organs: COVID-19 outbreak in Iran. New Microbes New Infect 38: 100792, 2020.
21. Alhenc-Gelas F and Drueke TB: Blockade of SARS-CoV-2 infec¬tion by recombinant soluble ACE2. Kidney Int 97: 1091-1093, 2020.
22. Zhang L, Peng Y, Zheng Q, Jiang L, Tang S and Chen P: Retrospective analysis of clinical characteristics and laboratory results of COVID-19 patients. European Journal of Inflammation. January 2021. doi:10.1177/20587392211011919.
23. Kho J, Ioannou A, Van den Abbeele K, Mandal AKJ and Missouris CG: Pulmonary embolism in COVID-19: Clinical characteristics and cardiac implications. Am J Emerg Med 38: 2142-2146, 2020.
24. Zhang Y.Z., Holmes E.C. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell. 2020;181(2):223–227.
25. Guillen L, Padilla S, Fernandez M, Agullo V, Garcia JA, Telenti G, Garcia-Abellan J, Botella A, Gutierrez F and Masia M: Preemptive interleukin-6 blockade in patients with COVID-19 Sci Rep 10: 16826, 2020
26. Gao Y., Li T., Han M., Li X., Wu D., Xu Y. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, Su X and Cao B: SARS-CoV-2 and viral sepsis: Observations and hypotheses Lancet 395: 1517-1520, 2020
27. Ponti G, Maccaferri M, Ruini C, Tomasi A and Ozben T: Biomarkers associated with COVID-19 disease progression Crit Rev Clin Lab Sci 57: 389-399, 2020
28. Huang I, Pranata R, Lim MA, Oehadian A and Alisjahbana B: C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: A meta-analysis Ther Adv Respir Dis 14: 1753466620937175, 2020
29. Weidmann MD, Ofori K and Rai AJ: Laboratory Biomarkers in the management of patients with COVID-19 Am J Clin Pathol 155: 333-342, 2021
30. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034
31. Yazdanpanah F, Hamblin MR and Rezaei N: The immune system and COVID-19: Friend or foe? Life Sci 256: 117900, 2020
32. Zhang L and Guo H: Biomarkers of COVID-19 and technologies to combat SARS-CoV-2 Adv Biomark Sci Technol 2: 1-23, 2020
33. South AM, Brady TM and Flynn JT: ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor blocker use during the Pandemic: The Pediatric perspective Hypertension 76: 16-22, 2020
34. Li K., Wu J., Wu F., Guo D., Chen L., Fang Z. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol. 2020;55(6):327–331.
35. Adhikari IP, Tiwari R and Bala R: Estimation of the De Ritis ratio in the cases of chronic alcoholic liver disease attending OPD of a tertiary health care level institute of Kanpur, UP PARIPEX-Indian J Res 7: 219-221, 2018
36. Zhang J.J., Dong X., Cao Y.Y., Yuan Y.D., Yang Y.B., Yan Y.Q. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy Eur J Allergy Clin Immunol. 2020
37. Yazar H, Kayacan Y and Ozdin M: De Ritis ratio and biochemical parameters in COVID-19 patients Arch Physiol Biochem: 1-5, 2020 (Epub ahead of print)
38. Zinellu A, Arru F, De Vito A, Sassu A, Valdes G, Scano V, Zinellu E, Perra R, Madeddu G, Carru C, et al: The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients Eur J Clin Invest 51: e13427, 2021
39. Li G., De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Nat Rev Drug Discov. 2020;19(3):149–150.
40. Qin C, Wei Y, Lyu X, Zhao B, Feng Y, Li T, Cao H, Yang X, Zhou X, Wang W, et al: High aspartate aminotransferase to alanine aminotransferase ratio on admission as risk factor for poor prognosis in COVID-19 patients Sci Rep 10: 16496, 2020
41. Law H.K., Cheung C.Y., Ng H.Y., Sia S.F., Chan Y.O., Luk W. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106 (7): 2366–2374.
42. Varim C, Yaylaci S, Demirci T, Kaya T, Nalbant A, Dheir H, Senocak D, Kurt R, Cengiz H and Karacaer C: Neutrophil count to albumin ratio as a new predictor of mortality in patients with COVID-19 infection Rev Assoc Med Bras (1992) 66 (Suppl 2): S77-S81, 2020
43. Ucciferri C, Caiazzo L, Di Nicola M, Borrelli P, Pontolillo M, Auricchio A, Vecchiet J and Falasca K: Parameters associated with diagnosis of COVID-19 in emergency department Immun Inflamm Dis 9: 851-861, 2021.
44. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054–1062.